£1.2M
The seed round was led by Playfair Capital and will support product development and team expansion.
"Many people living with cancer feel isolated and unsupported, and traditional routes of delivering healthcare struggle to address these issues. It’s also imperative that we gather the necessary data to understand how cancer therapies affect not just survival, but quality of life, so that patients and doctors can weigh up this information to make informed decisions about their care. At Vine, our goal is to put patients back in control."
